Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults.
Adult
Antibodies, Bacterial
/ blood
B-Lymphocytes
/ immunology
Cholera
/ prevention & control
Cholera Vaccines
/ administration & dosage
Female
Haiti
Humans
Immunologic Memory
Male
O Antigens
/ blood
Time Factors
Vaccination
/ methods
Vaccines, Inactivated
/ administration & dosage
Vibrio cholerae
/ immunology
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
18
05
2018
accepted:
05
12
2018
revised:
12
02
2019
pubmed:
1
2
2019
medline:
24
4
2019
entrez:
1
2
2019
Statut:
epublish
Résumé
The bivalent killed whole-cell oral cholera vaccine (BivWC) is being increasingly used to prevent cholera. The presence of O-antigen-specific memory B cells (MBC) has been associated with protective immunity against cholera, yet MBC responses have not been evaluated after BivWC vaccination. To address this knowledge gap, we measured V. cholerae O1-antigen MBC responses following BivWC vaccination. Adults in St. Marc, Haiti, received 2 doses of the BivWC vaccine, Shanchol, two weeks apart. Participants were invited to return at days 7, 21, 44, 90, 180 and 360 after the initial vaccination. Serum antibody and MBC responses were assessed at each time-point before and following vaccination. We observed that vaccination with BivWC resulted in significant O-antigen specific MBC responses to both Ogawa and Inaba serotypes that were detected by day 21 and remained significantly elevated over baseline for up to 12 months following vaccination. The BivWC oral cholera vaccine induces durable MBC responses to the V. cholerae O1-antigen. This suggests that long-term protection observed following vaccination with BivWC could be mediated or maintained by MBC responses.
Identifiants
pubmed: 30703094
doi: 10.1371/journal.pntd.0007057
pii: PNTD-D-18-00798
pmc: PMC6372202
doi:
Substances chimiques
Antibodies, Bacterial
0
Cholera Vaccines
0
O Antigens
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007057Subventions
Organisme : NIAID NIH HHS
ID : R01 AI099243
Pays : United States
Organisme : NIDDK NIH HHS
ID : R25 DK103579
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI106878
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI089721
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Scand J Immunol. 2006 Sep;64(3):251-9
pubmed: 16918694
Mucosal Immunol. 2009 Jul;2(4):331-9
pubmed: 19404246
Infect Immun. 2009 Sep;77(9):3850-6
pubmed: 19528207
Lancet. 1990 Feb 3;335(8684):270-3
pubmed: 1967730
Infect Immun. 2010 Jan;78(1):253-9
pubmed: 19858296
Clin Vaccine Immunol. 2011 May;18(5):844-50
pubmed: 21346055
Clin Infect Dis. 2011 Jun;52(11):1343-9
pubmed: 21498389
Bioconjug Chem. 2011 Oct 19;22(10):2179-85
pubmed: 21899371
Clin Vaccine Immunol. 2012 May;19(5):690-8
pubmed: 22441386
Bull World Health Organ. 2012 Mar 1;90(3):209-218A
pubmed: 22461716
Clin Vaccine Immunol. 2012 Jun;19(6):842-8
pubmed: 22518009
J Immunol Methods. 2013 May 31;391(1-2):50-9
pubmed: 23454005
Clin Vaccine Immunol. 2013 Oct;20(10):1541-8
pubmed: 23925888
Am J Trop Med Hyg. 2014 May;90(5):873-81
pubmed: 24686738
PLoS Negl Trop Dis. 2014 May 01;8(5):e2828
pubmed: 24786645
PLoS Negl Trop Dis. 2015 May 29;9(5):e0003809
pubmed: 26023778
PLoS Negl Trop Dis. 2015 Jul 08;9(7):e0003881
pubmed: 26154421
PLoS Med. 2015 Nov 17;12(11):e1001901
pubmed: 26576044
PLoS Negl Trop Dis. 2016 Jun 16;10(6):e0004753
pubmed: 27308825
MBio. 2016 Dec 20;7(6):
pubmed: 27999163
Chembiochem. 2017 Apr 18;18(8):799-815
pubmed: 28182850
Wkly Epidemiol Rec. ;92(32):437-42
pubmed: 28799734
PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376
pubmed: 29624592
Vaccine. 2018 May 11;36(20):2768-2773
pubmed: 29655627
J Infect Dis. 1988 Jul;158(1):60-9
pubmed: 3392421
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10795-9
pubmed: 7526379
Vaccine. 1996 Feb;14(2):162-6
pubmed: 8852414